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Abstract
Background: Ovarian and triple-negative breast cancers with BRCA1 or BRCA2 loss are highly sensitive to treatment
with PARP inhibitors and platinum-based cytotoxic agents and show an accumulation of genomic scars in the form
of gross DNA copy number aberrations. Cancers without BRCA1 or BRCA2 loss but with accumulation of similar
genomic scars also show increased sensitivity to platinum-based chemotherapy. Therefore, reliable biomarkers to
identify DNA repair-deficient cancers prior to treatment may be useful for directing patients to platinum chemotherapy
and possibly PARP inhibitors. Recently, three SNP array-based signatures of chromosomal instability were published that
each quantitate a distinct type of genomic scar considered likely to be caused by improper DNA repair. They measure
telomeric allelic imbalance (named NtAI), large scale transition (named LST), and loss of heterozygosity (named
HRD-LOH), and it is suggested that these signatures may act as biomarkers for the state of DNA repair deficiency in
a given cancer.
Results: We explored the pan-cancer distribution of scores of the three signatures utilizing a panel of 5371 tumors
representing 15 cancer types from The Cancer Genome Atlas, and found a good correlation between scores of the
three signatures (Spearman’s ρ 0.73–0.87). In addition we found that cancer types ordinarily receiving platinum as
standard of care have higher median scores of all three signatures. Interestingly, we also found that smaller
subpopulations of high-scoring tumors exist in most cancer types, including those for which platinum chemotherapy is
not standard therapy.
Conclusions: Within several cancer types that are not ordinarily treated with platinum chemotherapy, we identified
tumors with high levels of the three genomic biomarkers. These tumors represent identifiable subtypes of patients
which may be strong candidates for clinical trials with PARP inhibitors or platinum-based chemotherapeutic regimens.
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Background
Personalized medicine in cancer aims to improve treat-
ment outcome by matching the specific biological charac-
teristics of a tumor with the most appropriate therapeutic
option. One such biological characteristic is a defect in
one of the DNA repair systems, which often leads to the
accumulation of genomic damage, such as point muta-
tions and short indels, as well as gross copy number aber-
rations, termed genomic scars, that may be gain or loss of
large chromosomal regions, or even whole chromosomes
[1,2]. The ability to repair DNA is a fundamental require-
ment to sustain cellular life, and thus multiple partially re-
dundant repair pathways have evolved [3]. DNA repair
defects are one determinant of therapeutic response to
many chemotherapeutic agents. Depending on the type of
DNA repair defects present, cancers may show increased
sensitivity to treatment with certain DNA-damaging
agents or drugs that interfere with other parts of the DNA
repair system. This has been shown in particular with
BRCA1 and BRCA2, key genes in both the homologous
recombination (HR) and Fanconi Anemia (FA) pathways
[4-6]. Ovarian and breast tumors with loss of either
BRCA1 or BRCA2 are particularly sensitive to treatment
with platinum-based DNA crosslinking agents [7-10]. In
addition, loss of BRCA1/2 also causes sensitivity to inhib-
ition of PARP1, a key gene in the base excision repair
pathway and the target of several inhibitors currently
undergoing clinical evaluation [3,11,12]. However, some
tumors with no apparent loss of BRCA1 or BRCA2 exhibit
similar patterns of genomic scars, and also show increased
sensitivity to treatment with platinum drugs [8,13,14].
This suggests that defects in DNA repair other than
BRCA1 or BRCA2 loss may also confer drug sensitivities
similar to BRCA1/2 loss. As the patterns of genomic scars
may be DNA repair pathway-specific rather than gene-
specific, drug response signatures based on genomic scars
may be reliable biomarkers for DNA repair deficiency and
could be used to identify patients that would benefit from
specific types of anti-cancer therapy [15].
Three signatures, each measuring a specific type of
genomic scar in SNP array data, were published in 2012
by three groups, including ours. The Number of telo-
meric Allelic Imbalances (NtAI), published by us, was
based on a type of genomic scar accumulation which
could predict response to platinum-based chemotherapy
in triple negative breast cancer (TNBC, expressing nei-
ther estrogen, progesterone, nor HER2 receptors) and
high grade serous ovarian cancer [8]. Large ScaleTransition
(LST), published by Popova et al., was based on a type of
genomic scar which was associated with loss of BRCA1 or
BRCA2 in TNBC [13]. The Homologous Recombination
Deficiency score (HRD-LOHa), published by Abkevich
et al., was based on a type of genomic scar that was
enriched in high grade serous ovarian cancer patients with
loss of BRCA1 or BRCA2 [14]. The genomic scars mea-
sured by each signature are defined differently, although it
is possible for a scar to be included in more than one signa-
ture (Figure 1). All three signatures are based on the
assumption that summary measures of a defined type of
genomic scar is proportional to the number of times an
established cancer experienced error-prone DNA repair of
a given type, which resulted in the measured genomic scar.
As these signatures measure similar genomic features
and have been designed for the same purpose of guiding
precision medicine, we here use The Cancer Genome
Atlas (TCGA) to determine the distribution of the three
signatures of genomic scars across 15 different cancer
types. We find that cases with high levels of each signature
can be found in 12 of the 15 cancer types, suggesting that
it may be possible to use genomic scar signatures to iden-
tify patients with DNA repair deficiency predictive of plat-
inum chemotherapy sensitivity prior to initiating therapy.
We also investigate the association between high levels of
each signature and increased ploidy, p53 loss, and other
measures of genomic instability.
Results
Distribution of signature scores across cancer types
We first determined the distribution of the scores of
each signature in the 15 cancer types (Figure 2, Table 1).
We observed a considerable variation in scores within
each cancer type, ranging from low to high levels of all
signature scores in most cancer types. This shows that
the type of chromosomal aberrations that are counted
by each signature is not restricted to a single or a few
types of cancer, but rather represents a general aberration
pattern that can be found across most cancer types. The
exceptions were acute myeloid leukemia (AML) and thy-
roid cancer, which predominantly showed low counts of
all three signatures. For AML, this is consistent with the
finding published by the TCGA consortium that this
cancer type has relatively stable genomes with an average
of just one somatic copy number event per case [16].
We compared the median signature counts across cancer
types and observed that the highest scoring cancer type for
the NtAI and LST signatures was serous ovarian cancer
(median NtAI = 24, LST = 20, Table 1) followed by squa-
mous cell lung cancer. Both of these cancer types were
high for HRD-LOH as well (LUSC = 17, OV = 15). Ser-
ous ovarian cancer is known to feature a high frequency
of HR deficiency, often caused by homozygous loss of
BRCA1 or BRCA2, either through germline or somatic
inactivating mutations, or through promoter methyla-
tion, and there are defects in a large number of other
DNA repair genes that could affect HR as well [17]. We
then ranked the cancer types by average NtAI, LST and
HRD-LOH scores (Table 1) and observed that the can-
cer types that are found at the top of the list typically
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include platinum-based chemotherapy as part of the
first line standard of care, whereas the cancer types
found with the lowest scores generally do not receive
platinum as first line standard therapy. However, both
advanced or recurrent endometrial and thyroid cancer
may receive platinum-based therapy. With endometrial
cancer, 50% shows NtAI of less than 3, and LST and
HRD-LOH of less than 2. But 25% also shows NtAI
scores ranging from 16 to 33, LST from 10 to 45, and
HRD-LOH from 10 to 29. This suggests that while the
majority are DNA repair proficient, there is a consider-
able subset of endometrial cancer patients that may
have DNA repair deficiency, which may predispose to
sensitivity to platinum-based therapy. When we investi-
gated this further, we found that a considerable fraction
of the endometrial cancers with low levels of genomic
scars also tested positive for microsatellite instability
(MSI). Indeed, almost all tumors with MSI showed low
levels of genomic scars across colon, gastric and endo-
metrial cancers, which were the three cancer types for
>10Mb
>15Mb
extends to
telomere
A B C NtAI LST HRD-LOH
Figure 1 Overview of the type of genomic scars measured by each HR signature. Dark and light grey are used to indicate paternal and maternal
chromosomes. A: Number of telomeric allelic imbalances (NtAI) counts the number of subtelomeric regions with allelic imbalance, that start
beyond the centromere and extend to the telomere. B: Large-scale state transitions (LST) counts the number of chromosomal breaks between
adjacent regions of at least 10 Mb. C: Homologous recombination deficiency score (HRD-LOH) measures the number of regions with LOH which
are larger than 15 Mb, but shorter than the whole chromosome.
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Figure 2 Distribution of signature scores across 15 cancer types. A: Distribution of NtAI scores. B: Distribution of LST scores. C: Distribution of
HRD-LOH scores. Horizontal black lines indicate 25th, 50th and 75th percentiles.
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which MSI was experimentally evaluated (Figure 3).
This apparent tendency towards mutual exclusivity sug-
gests that in MSI cancers, MSI arises before the gen-
omic instability that generates genomic scars, and that
there is no further selective advantage for the cancer
cells to develop additional genomic instability.
Notably, breast cancer is in the middle of the ranked
list. Breast cancer patients do not normally receive
platinum-based chemotherapy in the adjuvant or first
line metastatic setting. However, a subset of the triple-
negative breast cancers has recently been shown be highly
sensitive to cisplatin chemotherapy [7,10]. When we
analyze the signature scores separately for the three
subtypes, we do indeed find that TNBC shows much
higher signature scores than either of the ER/PR+ and
HER2+ subtypes (Additional file 1: Figure S1), with
TNBC showing median NtAI, LST and HRD-LOH
values of 27, 21.5 and 21, respectively. This is even
higher than the values observed for serous ovarian cancer,
suggesting a higher frequency of DNA repair deficiency.
Comparing genomic scar signature scores
To determine if tumors that scored high by one signa-
ture also scored high by the others, we first determined
the Spearman correlation coefficient (ρ) between each
pair of signature scores across all cancer types and
within each cancer type (Figure 4A). We found that
NtAI and LST generally showed a high correlation to
each other (Spearman’s ρ = 0.87), with ρ > 0.7 in 8 of 15
cancer types. HRD-LOH shows a lower level of correl-
ation with both NtAI (ρ = 0.81) and LST (ρ = 0.73), with
ρ > 0.7 in just 2 of 15 cancer types for both NtAI and
LST. Across cancer types, the three signatures showed
the best correlation to each other in endometrial cancer,
with ρ = 0.90 (NtAI vs. LST), 0.86 (NtAI vs. HRD-LOH),
and 0.83 (LST vs. HRD-LOH). This could indicate that
NtAI and LST measure overlapping genomic scars and
therefore give high scores to more similar subpopula-
tions of tumors, whereas the lower correlation to HRD-
LOH suggests that it is counting genomic scars of a
somewhat separate tumor subpopulation. To test this
hypothesis, we compared the actual genomic aberrations
measured by the three signatures. Here we found that
on average only 3.1% of all measured copy number
events were counted by all three signatures across can-
cer types (Figure 4B). Further, the number of chromo-
somal events counted by both NtAI and LST (11.4%)
was no higher than the number counted by NtAI and
HRD-LOH (11.4%) or LST and HRD-LOH (11.8%). This
shows that the high correlation between NtAI and LST
is not caused by an overlap in the individual events
counted. Instead, the high correlation could indicate that
the underlying repair defect generates multiple complex
genomic aberration patterns, and that the different
methods rely on capturing different non-overlapping
aspects of these patterns to estimate the overall DNA
repair competency.
Association between genomic scar signatures and other
measures of chromosomal instability
As NtAI, LST and HRD-LOH can be considered a type
of genomic instability score, we next compared the sig-
nature scores to three other previously published mea-
sures of chromosomal instability: the weighted genome
integrity index (wGII) [18], the frequency of LOH
(FLOH) [19], and the total number of mutations per
sample (Nmut) [20], Figure 5. We observed that both
NtAI and LST scores showed a good correlation with
wGII (median ρ = 0.75 and 0.64, respectively), whereas
HRD-LOH was lower, with a median ρ = 0.49. Correl-
ation to FLOH was lower for both NtAI and LST
(median ρ = 0.53 & ρ = 0.39), but HRD-LOH was consid-
erably higher with median ρ = 0.76. This is not surpris-
ing, since HRD-LOH is measuring a type of LOH. The
correlation to Nmut was much lower for all three signa-
tures, with ρ = 0.11, 0.16 and 0.16 for NtAI, LST and
HRD-LOH, respectively. This suggests that a simple
measure of mutation counts is not a good surrogate for
genomic scars as defined by either method, but that
more general measures of chromosomal instability such
as wGII and FLOH are correlated to these genomic scar-
based approaches.
Table 1 Median signature scores for each cancer type
Cancer Median
NtAI
Median
LST
Median
HRD-LOH
Average
ranking
Receives first
line platinum*
OV 24 20 15 1 Yes
LUSC 20 13 17 2 Yes
BLCA 16 11 9 3 Yes
HNSC 15 9 12 3 Yes
LUAD 15 10 11 3 Yes
BRCA 12 8 8 6 No
SKCM 9 6 7 7 Some
STAD 10 7 5 7 Yes
COAD 8 5 5 9 Yes
GBM 4 3 4 10 No
PRAD 4 6 2 11 No
KIRC 4 3 3 12 No
UCEC 3 2 2 13 No$
LAML 1 0 0 14 No
THCA 0 0 0 15 No$
*Based on treatment information available from Cancer Research UK, which
can be found via http://www.cancerresearchuk.org/about-cancer/type/ $Does
not receive chemotherapy as first line, but may receive platinum-based
chemotherapy for high stage or recurrent disease.
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Near-tetraploid tumors show increased NtAI and LST scores
Both the NtAI and LST signatures measure a genomic
aberration pattern where a single allelic event may in-
crease the score. As such, an increase in sample ploidy
increases the amount of DNA that may experience gen-
omic aberrations, and this may correlate with increased
signature counts. Indeed, in the original publication of
LST [13], Popova and colleagues showed that the
threshold for calling HR deficiency using LST should be
set higher for near-tetraploid tumors compared to near-
diploid tumors, at 20 versus 15. The HRD-LOH score
specifically measures LOH, the complete loss of one
parental allele. As ploidy increases beyond diploid,
complete LOH in the absence of selective pressure be-
comes less likely in a purely probabilistic sense, as the
generation of a region of LOH requires multiple events
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Figure 3 Distribution of NtAI, LST and HRD-LOH signature scores by MSI status in colon, gastric and endometrial cancer. Tumors are grouped by
MSI (microsatellite instable) or MSS (microsatellite stable). Horizontal black lines indicate 25th, 50th and 75th percentiles.
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of genomic loss at the same site. Thus, the generation of
new HRD-LOH events is theoretically less likely to
occur as ploidy increases.
When we compared the signature scores in near-
diploid versus near-tetraploid cancers (see Methods), we
do indeed find that for both NtAI and LST, the mean
signature score is significantly increased in near-
tetraploid samples for 11 and 12 of 15 cancer types,
respectively (Additional file 2: Figure S2). This was
true for only 6 of 15 cancer types for HRD-LOH, and
additionally we found a significant decrease in the
HRD score in near-tetraploid ovarian cancer and
stomach adenocarcinoma (Additional file 3: Figure
S3). The fact that some cancer types showed signifi-
cantly increased HRD-LOH scores in near-tetraploid
tumors could indicate that these cancer types are
prone to undergo a late tetraploidization step in an
already established cancer, where parental alleles have
already been lost due to chromosomal instability in a
diploid state.
Tumors with p53 mutations show increased NtAI, LST and
HRD-LOH scores
As both TNBC and serous ovarian cancer commonly
have p53 mutations, we tested if p53 status itself would
be associated with increased scores of NtAI, LST and
HRD-LOH. We examined cancer types with at least 20
samples with P53 loss, and at least 20 samples with
wtP53. We found that all showed a significant increase
in the scores of all signatures in mP53, with the exception
of melanoma and stomach adenocarcinoma for LST, and
melanoma for HRD-LOH (Additional file 4: Figure S4).
As p53 loss is often associated with genomic instability
and increased ploidy states, we also compared the p53 sta-
tus of near-diploid and near-tetraploid samples. Overall,
we found that 44% of near-diploid tumors showed p53
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Figure 4 Comparison between signature scores. A: Spearman correlation coefficients for signature pairs. B: Venn diagram showing the overlap of
genomic scars counted by the three signatures. All breakpoints measured by one or more signatures were counted, and each area gives the
percentage of those breakpoints that were measured by each signature or combination of signatures.
Figure 5 Comparison of signature scores to other measures of genome instability. Spearman correlation coefficients between each of the three
HR signatures (NtAI, LST and HRD-LOH) and each of three alternative genomic signatures (wGII, FLOH and Nmut, see text for details).
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mutations (1177 out of 2690), whereas 74% of near-
tetraploid tumors showed p53 mutation (1443 out of
1953. Odds ratio = 3.64, p < 0.0001, Fisher’s exact test).
Stage and grade are not consistently associated with high
NtAI, LST and HRD-LOH scores
Stage was available for 12 of 15 cancer types. When we
compared NtAI, LST and HRD-LOH in samples with
low (stage 1 + 2) versus high stage (stage 3 + 4), we found
that high stage was significantly associated with higher
NtAI and LST scores in breast and head and neck can-
cer, and with higher of all three scores in colon, renal,
and endometrial cancer (Additional file 5: Figure S5).
Grade was available for only 6 of 15 cancer types. Of
these, all three scores were significantly higher in high
grade (3–4) bladder, renal and endometrial cancer. How-
ever, for stomach adenocarcinoma all three scores showed
a significantly lower signature score in high grade tumors
(Additional file 6: Figure S6).
Smoking associates with high NtAI, LST and HRD-LOH
scores in lung adenocarcinoma and head and neck cancer
Tobacco smoke is a known carcinogen, and highly associ-
ated with lung cancer and head and neck cancer. If to-
bacco smoke also causes increased levels of DNA damage
that results in genomic scaring measured by either pre-
dictor, we would expect to find higher counts of NtAI,
LST, and HRD-LOH in patients that smoke compared to
non-smokers. Clinical annotations regarding the patient
smoking history were available for adeno and squamous
cell lung cancer, head and neck cancer, and bladder can-
cer. We grouped patients currently smoking with pa-
tients that stopped smoking within the past 15 years
(“smokers”), and compared these to patients that never
smoked, or stopped smoking at least 15 years ago
(“non-smokers”). This showed a clear increase in the
median NtAI, LST and HRD-LOH counts for smokers
relative to non-smokers in head and neck cancer patients
(median NtAI: 17 versus 12; LST: 10 versus 8, HRD-LOH:
13 versus 9), and in lung adenocarcinoma cancer (median
NtAI: 18 versus 12, LST: 13 versus 8, HRD-LOH: 14
versus 9). No significant difference was found for bladder
or squamous cell lung cancer (Additional file 7: Figure S7).
Discussion
In this study we performed a comprehensive analysis of
5371 tumors representing 15 cancer types, to investigate
the distribution of previously characterized genomic
scars associated with HR deficiency, a DNA repair defi-
ciency that causes increased sensitivity to platinum-
based genotoxic chemotherapy and PARP inhibitors
[15]. We showed that the three signatures of genomic
scars demonstrate only limited overlap in the chromo-
somal events identified by each signature, yet there is a
good correlation between the total number of events
they identify in each sample. This suggests that the gen-
omic scars they measure are caused by identical or re-
lated DNA repair deficiencies, likely loss of different
elements in the HR pathway. Unfortunately it is not pos-
sible based on the current work to establish the true bio-
logical basis of these genomic scars. However, if the
difference between signature scores indeed represents
deficiencies in different elements of the HR pathway,
then it is plausible that sensitivity to therapy will be par-
ticularly high when all signatures are high. Conversely, if
the signatures all represent the same underlying biology,
then detection error will determine sensitivity, and one
high scoring signature could potentially predict for re-
sponse as well as if all three signatures are high. Further
studies are required to fully elucidate the true biological
nature of these signatures. Nevertheless, all three signa-
tures identify considerable subpopulations of tumors
with high signature scores within most cancer types,
including those not regularly treated with platinum
chemotherapy. This might indicate that small but identi-
fiable subpopulations of cancer patients exists that could
potentially benefit from genotoxic therapy, but are
currently not receiving it as standard of care.
Although it has been shown in breast and ovarian can-
cer that increased numbers of the genomic scars counted
by all three signatures is associated with response to
platinum-based therapies [8,13,14], this has not been
shown for any other cancer type. It is plausible that in
other cancer types, genomic scars counted by either
method may be caused by completely different mecha-
nisms, and hence tumors with high scores may or may
not show increased sensitivity to platinum-based therapies
or PARP inhibitors. Nevertheless, the observation of high
median scores in tumor types for which platinum is cur-
rently used as standard of care suggests that at least in
some additional tumor types, these signatures may indeed
predict for platinum response. This can only be fully re-
solved through future prospective trials.
Across cancer types, the tumors with high signature
scores often harbor p53 inactivation and a near-tetraploid
genome. Loss of p53 is known to cause genome instability
in part through deficiency in the G1/S checkpoint [21]
and render cells permissive of tetraploidization [22]. How-
ever, it has previously been reported that p53 loss is asso-
ciated with platinum resistance in ovarian cancer [23], and
that in basal-like breast cancer, tetraploidization was more
prevalent in tumors with wildtype BRCA1 than in tumors
harboring inactivation of BRCA1 [13]. This suggests that
the genomic scars caused by p53 inactivation and tetraploi-
dization, and which are measured by NtAI, LST or HRD-
LOH, arise through mechanisms that are unrelated to the
DNA repair deficiencies that are associated with sensitivity
to genotoxic agents. Further studies should therefore
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evaluate whether the signature thresholds used to predict
therapy response should be set higher for tumors with p53
inactivation and/or tetraploid genomes.
We observe higher values of NtAI, LST and HRD-
LOH for four cancer types often associated with tobacco
smoking: bladder, lung adenocarcinoma and squamous
cell cancer, and head and neck cancer. This suggests that
continuous exposure to a carcinogen that causes in-
creased levels of DNA damage may result in a higher
background level of copy number aberrations. However,
when we compared the levels of genomic scars in
current or recent smokers to those in non-smokers, we
observed lower levels of NtAI, LST and HRD-LOH in
the non-smoking population in lung adenocarcinoma
cancer and head and neck cancer, whereas there was no
difference between these groups in squamous lung and
bladder cancer. It is not clear why such a difference is
found, but it is possible that in lung adenocarcinoma
and head and neck cancer, smoking induces a cancer
type that is different from cancers arising outside of a
smoking context, whereas the mature phenotype of
squamous lung and bladder cancer may be more uniform
regardless of exposure to carcinogens from smoking.
In our investigation of the distribution of genomic
scars across cancer types, endometrial cancer was of par-
ticular interest. In endometrial cancer, the overall level
of genomic scars was very low, with a median of 3/2/2
for NtAI/LST/HRD-LOH scores. However, a significant
subset of microsatellite stable tumors showed a strong
increase in the genomic scar levels. In addition, there
was a highly significant association between higher levels
of genomic scars and both p53 mutation (Additional
file 4: Figure S4) and higher grade (Additional file 6:
Figure S6). As platinum chemotherapy is widely used as
standard of care for advanced endometrial carcinoma,
these results may warrant further exploration as to
whether the inclusion of a genomic scar-based bio-
marker might improve upon the stratification of these
patients for adjuvant chemotherapy.
Conclusions
Personalized medicine in cancer care holds great prom-
ise, but unfortunately most drugs currently in clinical
practice are not paired with specific biomarkers, and it is
therefore not possible to predict their effect on a given
patient prior to therapy. Platinum agents and other gen-
otoxic agents work by inducing intolerable levels of
DNA damage into cancer cells. These agents have
proven highly successful and remain the mainstay of
cancer chemotherapy across many cancer types, but to
this date the identification of biomarkers for efficacy of
genotoxic drugs has proven elusive. As cancer cells sen-
sitive to treatment with genotoxic agents have reduced
capacity to tolerate DNA damage, possibly through loss
of DNA repair factors, identifying biomarkers that indi-
cate cancer-specific DNA repair capacity may prove a
useful proxy for predicting sensitivity to genotoxic ther-
apy. Here, the concept of a DNA scar becomes poten-
tially useful as a measure of DNA repair capacity. If the
use of the genomic signatures of DNA scarring can be
validated in prospective clinical trials, this may turn
already widely used and highly potent drugs into effect-
ive targeted agents available to any cancer patient with a
sensitive tumor, regardless of its site of origin.
Methods
Datasets
From the TCGA data portal, dbGap accession no.
phs000178.v5.p5, we obtained Affymetrix SNP6 genotyping
data and clinical information for 5502 unique cancer sam-
ples representing 15 distinct cancer types, listed in Table 2.
Data processing
All data analysis was performed in the R statistical envir-
onment, version 3.0.1. Affymetrix SNP6 data from paired
tumor-normal samples were normalized and prepro-
cessed using the Aroma Affymetrix CRMAv2 algorithm
[24], and the B-allele fraction (BAF) was adjusted using
the CalMaTe and TumorBoost algorithms [25,26].
Tumor copy number aberrations, ploidy and normal cell
contamination was determined using ASCAT [27]. Tu-
mors with aberrant cell fraction (ACF) below 0.36 was
excluded from the analysis.
Table 2 Number of samples per cancer type in the
present analysis
TCGA
code
Cancer type Number of
samples
BLCA Bladder urothelial carcinoma 127
BRCA Breast invasive carcinoma 877
COAD Colon adenocarcinoma 380
GBM Glioblastoma multiforme 456
HNSC Head and neck squamous cell
carcinoma
294
KIRC Kidney renal clear cell carcinoma 433
LAML Acute myeloid leukemia 153
LUAD Lung adenocarcinoma 305
LUSC Lung squamous cell carcinoma 241
OV Ovarian serous cystadenocarcinoma 512
PRAD Prostate adenocarcinoma 325
SKCM Skin cutaneous melanoma 244
STAD Stomach adenocarcinoma 163
THCA Thyroid carcinoma 438
UCEC Uterine corpus endometrial
carcinoma
423
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Implementing genomic signatures
We implemented algorithms to quantify each of the gen-
omic scar signatures in R. All signature scores are avail-
able in Additional file 8: Table S1, and the code is
available in Additional file 9. The signatures were imple-
mented following the directions described in the original
publications [8,13,14] with two exceptions: 1) The original
publication describing HRD-LOH [14] excluded chromo-
some 17 because LOH on chromosome 17 in the ovarian
cancer samples is ubiquitous and for this reason did not
provide independent information. We decided to not ex-
clude chromosome 17, as chromosome 17 is not ubiqui-
tously lost in all cancer types, and therefore may provide
independent information in some tumor samples. 2) In
the original publication describing NtAI [8], we counted
all allelic imbalance events that extended to the telomere,
if they did not span the centromere. In subsequent work,
we have found that this occasionally biases samples with
an uneven chromosome count. If e.g. triploid chromo-
somes have an independent interstitial copy number event
of sufficient size between telomere and centromere, it was
counted as an NtAI event. This results in an overrepresen-
tation of tumors with an uneven copy number among
high NtAI cases, which has been corrected in the method
used for the present study. In the implementation of the
NtAI method used here, we determine the major copy
number state for each chromosome independently, de-
fined as the copy number state of the majority of the
chromosome that is greater than zero. We then count
NtAI events only if these deviate from the main copy
number state of a given chromosome, while taking allelic
contribution into account (Additional file 1: Figure S1).
Mutation data to determine the total number of mutations
(Nmut) was defined as the number of called base substitu-
tions, indels, and dinucleotide mutations [20], and was
based on the curated dataset provided in the supplemen-
tary data from [28]. The frequency of LOH (FLOH) was
determined as described [19].
Sample ploidy estimate
The ploidy of each tumor is determined as part of the
ASCAT modeling of the log2 copy number data and the
B-allele frequency data. DNA index is defined as the
tumor ploidy divided by the expected ploidy of 2. Based
on the hypothesis that duplication of the whole genome
during cancer progression is the most common initiation
event for aneuploidy [29], samples with a DNA index >
1.2 are considered near-tetraploid in a manner similar to
[13], whereas tumors with DNA index < 1.2 are consid-
ered as near-diploid.
Data analysis
We used Spearman’s rank correlation coefficient (ρ) to
measure concordance between continuous signature
scores. The Wilcoxon rank sum test was used to test for
increase in signature scores by ploidy. All p-values are
two-sided.
Endnote
aIn the original publication [14] this method was re-
ferred to as “HRD”. This term is currently used to de-
scribe a score that combines NtAI, LST and HRD [30],
and subsequently the recognised term for the original
method described in [14] is currently “HRD-LOH”,
which is therefore also used throughout this text.
Additional files
Additional file 1: Figure S1. The effect of sample ploidy on NtAI
calling. A: Scatter plot showing updated versus original NtAI score per
sample, based on the TCGA ovarian cancer cohort. The colors and shapes
indicate the ploidy state of the tumor. Tumors with ploidy state below 2
or above 4 are shown as unfilled black circles.
Additional file 2: Figure S2. Signature scores in breast cancer subtypes
Distribution of signature scores in ER-positive, HER2-positive and triple
negative breast cancers.
Additional file 3: Figure S3. Signature scores by ploidy. Mean signatures
scores for near-diploid and near-tetraploid tumors across cancer types. A:
NtAI, B: LST, C: HRD-LOH. Sample ploidy is defined as DNA index < 1.2 for
near-diploid, or > 1.2 for near-tetraploid.
Additional file 4: Figure S4. Signature scores by p53. Distribution of
signature scores in tumors with wildtype and mutant p53.
Additional file 5: Figure S5. Signature scores by stage. Distribution of
signature scores by tumor stage. Low stage is defined as stage 1–2; high
stage is defined as stage 3–4.
Additional file 6: Figure S6. Signature scores by grade. Distribution of
signature scores by tumor grade. Low grade is defined as grade 1–2;
high grade is defined as grade 3–4.
Additional file 7: Figure S7. Signature scores by smoking status.
Distribution of signature scores by smoking status. A non-smoker is
defined as a never-smoker or non-smoker for at least 15 years. A smoker
is defined as a current or recent smoker (<15 years).
Additional file 8: Table S1. The calculated signature scores along with
other measures of chromosomal instability are provided for all tumors
included in the present analysis.
Additional file 9: Supplementary methods. R source code with
implementations of the algorithms to quantify NtAI, LST and HRD-LOH.
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